8.20Open7.80Pre Close6 Volume200 Open Interest150.00Strike Price4.92KTurnover50.30%IV4.62%PremiumJan 17, 2025Expiry Date1.22Intrinsic Value100Multiplier24DDays to Expiry6.98Extrinsic Value100Contract SizeAmericanOptions Type0.5594Delta0.0202Gamma17.58Leverage Ratio-0.1708Theta0.0502Rho9.84Eff Leverage0.1533Vega
Glaukos Stock Discussion
$Arcutis Biotherapeutics (ARQT.US)$ : Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$
im seeing some decent chart upside here
thoughts?
$SciSparc (SPRC.US)$ rallied Wednesday, climbing over 20%, after the Israeli pharmaceuticals company said the psychedelic-based MEAI drug candidate developed with Canadian collaborator Clearmind Medicine produced a significant decrease in coccaine craving in rats compared to those in a non-treated control group during pre-clinical testing.
$Glaukos (GKOS.US)$ gained 6% after We...
• $Canoo (GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $Aldeyra Therapeutics (ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $Westport Fuel (WPRT.US)$ +10.9% (awarded 38 mln program)
• $Greenwich LifeSciences (GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...
No comment yet